Table SII. Case reports included in the meta-analysis

Study/year/country	Patients	Intervention	Outcome	Adverse effects
Ambika et al. (19), 2013/India	n=1, (M: 1) (Type: Sup: 1)	0.5% timolol BD Age at initiation: 3 months, Duration: 3 months	Assessed by photography Complete resolution	No side effects, no rebound
Beal et al. (20), 2014/USA	n=1, (M: 1) (Type: Sup: 1)	0.5% timolol BD Age at initiation: 3 months Duration: 3 months	Assessed by photography Complete resolution	No side effects, no rebound
Calvo et al. (21), 2013/Spain	n=1, (M: 1) (Type: Sup: 1)	0.5% timolol BD Age at initiation: 3 months Duration: 3 months	Assessed by photography Complete resolution	No side effects, no rebound
Chang et al. (26), 2014/USA	n = 1, (F: 1) (Type: Sup: 1)	0.25% timolol BD then 0.5% timolol BD Age at initiation: 3 months Duration: 3 months	Assessed by photography Complete resolution	No side effects, no rebound
Cante et al. (22), 2012/France	n=2, (M: 1,F: 1) (Type: Sup: 2)	0.5% timolol BD in 1/2 and OD in 1/2 Age at initiation: 4.5 months Duration: 7.5 months	Assessed by photography Complete resolution	No side effects, no rebound
Chu et al. (27), 2013/USA	n=3, (M: 1,F: 2) (Type: Sup: 3)	0.5% timolol-brimondine BD Age at initiation: 4 months Duration: 3 months	Assessed by photography Complete resolution	No side effects, rebound reported 1/3
Ciudad et al. (28), 2015/Spain	n=1, (F: 1) (Type: Sup: 1)	0.5% timolol BD Age at initiation: 5 months Duration: 5 months	Assessed by photography Complete resolution	No side effects, no rebound
Fernandez et al. (29), 2012/ Spain	n=1, (M: 1) (Type: Sup: 1)	0.1% timolol BD Age at initiation: 2 months Duration: 4 months	Assessed by photography Complete resolution	No side effects, no rebound
Guo et al. (15), 2010/USA	n=1, (F: 1) (Type: Sup: 1)	0.5% timolol BD Age at initiation: 4 months Duration: 1.75 months	Assessed by photography Complete resolution	No side effects, no rebound
Jha et al. (30), 2012/India	n=1, (M: 1) (Type: Sup: 1)	0.5% timolol BD Age at initiation: 6 months Duration: 1.25 months	Assessed by photography Complete resolution	No side effects, no rebound
Matuszczak et al. (31), 2013/ Poland	n=1, (F: 1) (Type: Sup: 1)	timolol BD Age at initiation: 13 months Duration: 3 months	Assessed by photography Complete resolution	No side effects, no rebound
Rizvi et al. (38), 2015/India	n=2, (M: 1,F;1) (Type: Sup: 2)	0.5% timolol BD Age at initiation: 1.5 months Duration: 12 months	Assessed by photography Complete resolution	No side effects, no rebound
Semkova et al. (40), 2014/ Bulgaria	n=1, (M: 1) (Type: Sup: 1)	0.1% timolol 4 times daily Age at initiation: 3 months Duration: 2 months	Assessed by photography Complete resolution	No side effects, no rebound
Sorrell et al. (41), 2013/USA	n=3, (M: 2, F: 1)(Type: Deep: 3)	0.5% timolol BD Age at initiation: 2.58 months Duration: 3 months	Assessed by photography Complete resolution	No side effects, no rebound
Thomas et al. (43), 2013/India	n=1, (F: 1) (Type: Sup: 1)	0.5% timolol BD Age at initiation: 0.57 months Duration: 3 months	Assessed by photography Complete resolution	No side effects, no rebound
Weissenstein et al. (44), 2012/ Germany	<i>n</i> = 1, (Type: Sup: 1)	0.1% timolol BD Age at initiation: 5.5 months Duration: 0.5 months	Assessed by photography Complete resolution	No side effects, no rebound
Weissenstein et al. (45), 2012/ Germany	n = 1, (Type: Sup: 1)	0.5% timolol BD Duration: 4 months	Assessed by photography Complete resolution	No side effects, no rebound
Xue et al. (47), 2013/UK	n=2, (Deep: 2)	0.5% timolol BD Age at initiation: 3.8 months Duration: 10.5 months	Assessed by photography Complete resolution	No side effects, no rebound

IH: infantile hemangioma; Sup: superficial hemangioma; Tx: treatment; VAS: visual analogue scale; BD: twice daily. GFS: Gel forming solution; TDS: thrice daily.